Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to explore the effeicency and toxicities of rituximab combined with
chidamide and lenalidomide in patients with relapsed or refractory AITL.